Abstract 4371699: Asymptomatic Brain Injury: A Common Finding After Pulsed Field Ablation of Uncertain Significance — A Systematic Review and Meta-Analysis

J Juan Rodriguez-Riascos (Mayo Clinic Arizona, Scottsdale, Arizona, United States) X Xuan Ci Mee (Mayo Clinic, Phoenix, Arizona, United States) H Hema Vemulapalli (Mayo Clinic, Phoenix, Arizona, United States) R Ricardo Estrada-Mendizabal (Mount Sinai NYCHH Elmhurst, Jackson Heights, New York, United States) R Regash Mariajohn (American International Medical University, St. Lucia, Saint Lucia) B Bala Vignesh Kalyanasundaram (Mayo Clinic, Phoenix, Arizona, United States) M Michael Liu K Komandoor Srivathsan (Mayo Clinic, Phoenix, Arizona, United States)

Abstract

Background: Pulsed field ablation (PFA) has become a cornerstone for atrial fibrillation ablation. Multiple platforms have been developed and approved worldwide, and routine screening for asymptomatic brain injury (ABI) has been included in several trials as part of the safety assessment of this technology. The incidence by catheter/platform, predictors of occurrence, and clinical impact remain incompletely understood. Research Question: In patients with atrial fibrillation undergoing pulmonary vein isolation, does the incidence of ABI vary between different PFA platforms? Methods: We searched the MEDLINE/PubMed, Embase, and Cochrane Central Register of Controlled Trials databases for studies reporting on patients who underwent PFA and post-procedure brain MRI to screen for ABI. The review was conducted in accordance with PRISMA guidelines. A random-effects proportion meta-analysis was performed, with subgroup analysis based on the PFA platform used. For studies including a thermal ablation control group, risk ratio (RR) was used to compare outcomes. Finally, a meta-regression was conducted to identify potential predictors of ABI incidence. Results: A total of 19 studies reporting data from 742 patients who underwent post-ablation brain MRI were included in this review. The pooled incidence of silent cerebral events (new findings visible only on DWI sequences) and silent cerebral lesions (new findings on both DWI and FLAIR sequences) was 5% each (95% CI, 3%–8%). The pooled incidence of any ABI was 10% (95% CI, 8%–13%). A platform-level subgroup analysis demonstrated comparable outcomes across the platforms with available data (Figure 1). The meta-regression included age, sex, CHA2DS2-VASc score, and incidence of symptomatic stroke/TIA, but no statistically significant associations were identified. In the four studies that included a thermal ablation control group, there was no significant difference in ABI incidence between PFA and thermal ablation (RR: 1.37; 95% CI, 0.68–2.74; P = 0.38; I2 = 16%) (Figure 2). Seven studies reported follow-up MRI in patients who presented with an ABI. Among 20 patients with ABI after ablation, radiologic lesions persisted in 2 patients. Conclusion: ABI is a relatively frequent finding following PFA; however, current evidence does not reveal significant differences between available platforms. Radiologic findings tend to be transient, suggesting a limited long-term clinical impact.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (8)

J

Juan Rodriguez-Riascos

Mayo Clinic Arizona, Scottsdale, Arizona, United States

X

Xuan Ci Mee

Mayo Clinic, Phoenix, Arizona, United States

H

Hema Vemulapalli

Mayo Clinic, Phoenix, Arizona, United States

R

Ricardo Estrada-Mendizabal

Mount Sinai NYCHH Elmhurst, Jackson Heights, New York, United States

R

Regash Mariajohn

American International Medical University, St. Lucia, Saint Lucia

B

Bala Vignesh Kalyanasundaram

Mayo Clinic, Phoenix, Arizona, United States

M

Michael Liu

K

Komandoor Srivathsan

Mayo Clinic, Phoenix, Arizona, United States